|
 |
 |
|
 |
 |
MAY
30, 2008
Contemporary Strategies for Abrogating Immunologic Tolerance
to Melanoma
An Independent Satellite Symposium Adjunct to the 44th ASCO® Annual Meeting
6:30pm – 8:30pm
Sheraton Chicago Hotel and Towers
Chicago Ballroom 6 & 7
Chicago, Illinois
Chair
Jeffrey S. Weber, MD, PhD
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida
Click here to register for this program |
 |
| F
A C U L T Y |
 |
|
Paul B. Chapman, MD
Memorial Sloan-Kettering Cancer Center
New York, New York
Steven O’Day, MD
The Angeles Clinic
Santa Monica, California |
Jeffrey S. Weber, MD, PhD
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida |
Jedd Wolchok, MD, PhD
Memorial Sloan-Kettering Cancer Center
New York, New York
|
|
|
| S
C I E N T I F I C A G E N D A |
|
|
6:30 pm
Welcome and introduction
Jeffrey S. Weber, MD, PhD
6:40 pm
The biology of melanoma and current therapeutic options
Paul B. Chapman, MD
7:00 pm
Molecular mechanisms of immunologic tolerance to cancer
Jedd Wolchok, MD, PhD
7:25 pm
Disinhibiting the immune system: Targeting CTLA-4 in the treatment of metastatic melanoma
Steven O’Day, MD
7:50 pm
Interactive case studies: Clinical response to anti-CTLA-4 antibodies and management of associated immune-related adverse events
Jeffrey S. Weber, MD, PhD
8:15 pm
Panel Discussion
8:30 pm
Adjourn |
|
|
| W
H O S H O U L D A T T E N
D |
|
|
| This activity is designed for medical oncologists, oncology surgeons, dermatologists, and other physicians and health professionals who manage melanoma patients and are involved in melanoma basic and clinical science research. |
|
|
| O
B J E C T I V E S |
|
|
After successful completion of this course, attendees should be able to:
- Provide an overview of melanoma genetics, epidemiology, and currently accepted management practices
- Analyze the rationale for novel targeted agents directed towards modulation of the immune response to melanoma
- Identify the clinical characteristics of CTLA-4 monoclonal antibodies including antitumor activity, kinetics of response and the nature of associated immune-related adverse events
- Describe case studies illustrating expected clinical characteristics of anti-CTLA-4 therapy and guidelines for management of associated immune-related adverse events
|
|
|
|
C O N T I N U I
N G M E D I C A
L E D U C A T I O N |
|
|
Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Imedex®, LLC designates this educational activity for a maximum of 2.0 AMA PRA Category 1 credits™. Physicians should only claim credit commensurate with their participation in the activity. |
|
|
| R E G I S T R A T I O N |
|
|
| This is a complimentary educational activity and space is limited. Please pre-register online at www.imedex.com. |
|
|
| G E N E R A L I N F O R M A T I O N |
|
|
Symposium Location
Sheraton Chicago Hotel and Towers
Chicago Ballroom 6 & 7
301 East North Water Street
Chicago, Illinois 60611
Tel: +1 (312) 646 1000
www.sheratonchicago.com
Transportation to and from the symposium is not provided |
|
|
| O
R G A N I Z E R |
|
|
|
| ©
2008 Imedex®, LLC |
|
